Literature DB >> 12435700

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.

Emiliana Tjitra1, Joanne Baker, Sri Suprianto, Qin Cheng, Nicholas M Anstey.   

Abstract

Artemisinin-derivative combination therapies (ACT) are highly efficacious against multidrug-resistant Plasmodium falciparum malaria. Few efficacy data, however, are available for vivax malaria. With high rates of chloroquine (CQ) resistance in both vivax and falciparum malaria in Papua Province, Indonesia, new combination therapies are required for both species. We recently found artesunate plus sulfadoxine-pyrimethamine (ART-SP) to be highly effective (96%) in the treatment of falciparum malaria in Papua Province. Following a preliminary study of CQ plus sulfadoxine-pyrimethamine (CQ-SP) for the treatment of Plasmodium vivax infection, we used modified World Health Organization criteria to evaluate the efficacy of ART-SP for the treatment of vivax malaria in Papua. Nineteen of 22 patients treated with ART-SP could be evaluated on day 28, with no early treatment failures. Adequate clinical and parasitological responses were found by day 14 in all 20 (100%) of the patients able to be evaluated and by day 28 in 17 patients (89.5%). Fever and parasite clearance times were short, with hematological improvement observed in 70.6% of the patients. Double (at positions 58 and 117) and quadruple (at positions 57, 58, 61, and 117) mutations in the P. vivax dihydrofolate reductase (PvDHFR) were common in Papuan P. vivax isolates (46 and 18%, respectively). Treatment failure with SP-containing regimens was significantly higher with isolates with this PvDHFR quadruple mutation, which included a novel T-->M mutation at residue 61 linked to an S-->T (but not an S-->N) mutation at residue 117. ART-SP ACT resulted in a high cure rate for both major Plasmodium species in Papua, though progression of DHFR mutations in both species due to the continued use of SP monotherapy for clinically diagnosed malaria threatens the future utility of this combination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435700      PMCID: PMC132782          DOI: 10.1128/AAC.46.12.3947-3953.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.

Authors:  E Tjitra; S Suprianto; B J Currie; P S Morris; J R Saunders; N M Anstey
Journal:  Am J Trop Med Hyg       Date:  2001-10       Impact factor: 2.345

2.  THE USE OF MEDICATED SALT IN AN ANTIMALARIA CAMPAIGN IN WEST NEW GUINEA.

Authors:  J H MEUWISSEN
Journal:  Trop Geogr Med       Date:  1964-09

3.  Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax.

Authors:  Ubolsree Leartsakulpanich; Mallika Imwong; Sasithon Pukrittayakamee; Nicholas J White; Georges Snounou; Worachart Sirawaraporn; Yongyuth Yuthavong
Journal:  Mol Biochem Parasitol       Date:  2002-01       Impact factor: 1.759

Review 4.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?

Authors:  C H Sibley; J E Hyde; P F Sims; C V Plowe; J G Kublin; E K Mberu; A F Cowman; P A Winstanley; W M Watkins; A M Nzila
Journal:  Trends Parasitol       Date:  2001-12

5.  Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia.

Authors:  E Tjitra; S Suprianto; M E Dyer; B J Currie; N M Anstey
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

6.  Factors contributing to anemia after uncomplicated falciparum malaria.

Authors:  R N Price; J A Simpson; F Nosten; C Luxemburger; L Hkirjaroen; F ter Kuile; T Chongsuphajaisiddhi; N J White
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

7.  Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli.

Authors:  R Tahar; P E de Pécoulas; L K Basco; M Chiadmi; A Mazabraud
Journal:  Mol Biochem Parasitol       Date:  2001-04-06       Impact factor: 1.759

8.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial.

Authors:  L von Seidlein; P Milligan; M Pinder; K Bojang; C Anyalebechi; R Gosling; R Coleman; J I Ude; A Sadiq; M Duraisingh; D Warhurst; A Alloueche; G Targett; K McAdam; B Greenwood; G Walraven; P Olliaro; T Doherty
Journal:  Lancet       Date:  2000-01-29       Impact factor: 79.321

9.  Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR.

Authors:  Reinaldo Teixeira Delfino; Osvaldo Andrade Santos-Filho; José Daniel Figueroa-Villar
Journal:  Biophys Chem       Date:  2002-08-02       Impact factor: 2.352

10.  Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance.

Authors:  Emiliana Tjitra; Sri Suprianto; Nicholas M Anstey
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Jul-Aug       Impact factor: 2.184

View more
  62 in total

1.  The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates.

Authors:  Sébastien Briolant; Hervé Bogreau; Marine Gil; Housem Bouchiba; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Authors:  Patricia Mula; Amalia Fernández-Martínez; Aida de Lucio; Jose Manuel Ramos; Francisco Reyes; Vicenta González; Agustín Benito; Pedro Berzosa
Journal:  Malar J       Date:  2011-08-02       Impact factor: 2.979

3.  Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax.

Authors:  R Suwanarusk; M Chavchich; B Russell; A Jaidee; F Chalfein; M Barends; B Prasetyorini; E Kenangalem; K A Piera; U Lek-Uthai; N M Anstey; E Tjitra; F Nosten; Q Cheng; R N Price
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

4.  Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.

Authors:  Céline Barnadas; Arsène Ratsimbasoa; Magali Tichit; Christiane Bouchier; Martial Jahevitra; Stéphane Picot; Didier Ménard
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 5.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 6.  Plasmodium vivax treatments: what are we looking for?

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey; Lorenz von Seidlein
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

7.  Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Sant Muangnoicharoen; Vipa Thanachartwet; Nutthanej Luplertlop; Siripan Srivilairit; Polrat Wilairatana; Shigeyuki Kano; Pascal Ringwald; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2007-06       Impact factor: 1.341

8.  Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan.

Authors:  Sedigheh Zakeri; Mandana Afsharpad; Faezeh Ghasemi; Ahmad Raeisi; Najibullah Safi; Waqar Butt; Hoda Atta; Navid D Djadid
Journal:  Malar J       Date:  2010-03-14       Impact factor: 2.979

9.  Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.

Authors:  Michael H Kinzer; Krisin Chand; Hasan Basri; Edith R Lederman; Augustina I Susanti; Iqbal Elyazar; George Taleo; William O Rogers; Michael J Bangs; Jason D Maguire
Journal:  Malar J       Date:  2010-04-06       Impact factor: 2.979

Review 10.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.